Neuropeptide Dysregulation in Chronic Pain Syndromes
Neuropeptides and Pain
30% of people
Chronic pain affects more than 30% of the global population, driven partly by neuropeptide systems that shift from protective signaling to pathological amplification.
Chen et al., Neuroscience Letters, 2026
Chen et al., Neuroscience Letters, 2026
View as imageAcute pain is a warning. Chronic pain is a malfunction. When pain persists beyond tissue healing, the neuropeptide systems that normally regulate pain signaling undergo persistent changes in expression, release, receptor density, and downstream signaling. Substance P gets overproduced. CGRP creates self-reinforcing feedback loops. Endogenous opioid peptides lose their inhibitory grip. Neuropeptide Y, which normally holds pain in check, gets depleted from the circuits where it is needed most. These shifts do not happen in isolation. They interact, compound, and create a neurochemical state where the nervous system amplifies pain rather than dampening it. Understanding which neuropeptides change, in which direction, and in which pain conditions is central to both diagnosing and treating chronic pain. The same molecular signals that make substance P measurable in fibromyalgia patients are the ones that explain why conventional painkillers often fail.
Key Takeaways
- Substance P and NK1 receptor expression increase in spinal cord dorsal horn neurons during chronic pain, driving central sensitization through enhanced excitatory transmission[1]
- Fibromyalgia patients show elevated serum levels of substance P, hemokinin-1, CRH, IL-6, and TNF compared to healthy controls, suggesting systemic neuropeptide dysregulation[5]
- Neuropeptide Y tonically inhibits chronic inflammatory and neuropathic pain; its loss after nerve injury removes a critical brake on pain signaling[3]
- CGRP creates a CREB-KIF1A-CGRP positive feedback loop in trigeminal neurons that drives central sensitization in chronic migraine[6]
- Mice lacking both Substance P and CGRP-alpha still experience pain, indicating that additional neuropeptide systems contribute to chronic pain beyond these two targets[2]
- The amygdala integrates neuropeptide signals from CRF, CGRP, substance P, and dynorphin to generate the emotional suffering component of chronic pain[4]
Substance P: The Amplifier That Won't Turn Off
In acute injury, substance P is released from C-fiber terminals in the spinal cord dorsal horn where it binds NK1 receptors on second-order neurons, amplifying pain transmission for the duration of the threat. In chronic pain, this system fails to reset.
Chen et al. (2026) reviewed the evidence for substance P/NK1 receptor involvement in central sensitization across chronic pain conditions.[1] Central sensitization, the process by which dorsal horn neurons become hyperexcitable and respond to normally innocuous stimuli, is now recognized as a core mechanism of chronic pain affecting more than 30% of people worldwide. Substance P contributes by increasing NK1 receptor expression on dorsal horn neurons, enhancing NMDA receptor activity (which lowers the threshold for excitatory transmission), and recruiting immune cells that release additional pro-inflammatory mediators.
The result is a system that stays activated long after the original tissue damage has resolved. Substance P levels in cerebrospinal fluid are elevated 2-3 fold in conditions including fibromyalgia, chronic regional pain syndrome, and chronic low back pain. Tsilioni et al. (2016) measured serum neuropeptide levels in 70 fibromyalgia patients and found that substance P, hemokinin-1 (HK-1), corticotropin-releasing hormone (CRH), IL-6, and TNF were all elevated compared to healthy controls.[5] This was not a localized finding. These neuropeptides were measurable in peripheral blood, indicating that fibromyalgia involves systemic neuropeptide dysregulation, not just spinal cord changes.
Alpay et al. (2025) examined substance P's role in the trigeminovascular system, where it contributes to migraine pathophysiology through neurogenic inflammation: vasodilation, plasma protein extravasation, and mast cell degranulation in the meninges.[7] Preclinical models show that substance P release from trigeminal afferents during migraine attacks is sustained rather than transient, and that chronic migraine patients have persistently elevated substance P levels between attacks. This ongoing baseline elevation represents a clear example of neuropeptide dysregulation: the peptide that should spike during an acute event instead remains chronically elevated.
Despite decades of investment, NK1 receptor antagonists (drugs designed to block substance P signaling) have consistently failed in clinical pain trials. MacDonald et al. (2025) provided a partial explanation: mice genetically engineered to lack both substance P and CGRP-alpha still experienced inflammatory and neuropathic pain at near-normal levels.[2] This finding suggests that while substance P dysregulation is a real feature of chronic pain states, blocking it alone is not sufficient to reverse the condition. The redundancy of pain signaling pathways means that other neuropeptides compensate when one is removed.
CGRP: Feedback Loops That Self-Amplify
Calcitonin gene-related peptide (CGRP) is the most therapeutically validated pain neuropeptide. Anti-CGRP monoclonal antibodies and receptor antagonists have transformed migraine treatment. But the success of CGRP-targeted drugs also reveals how deeply CGRP signaling becomes dysregulated in chronic pain.
Jiang et al. (2025) identified a molecular feedback loop that explains why CGRP stays elevated in chronic migraine.[6] In trigeminal ganglion neurons, CGRP activates CREB (a transcription factor), which upregulates KIF1A (a kinesin motor protein responsible for transporting neuropeptide vesicles along axons). More KIF1A means more CGRP-containing vesicles reach nerve terminals, which means more CGRP release, which means more CREB activation. This CREB-KIF1A-CGRP loop is self-sustaining: once triggered by repeated migraine attacks, it maintains elevated CGRP production and release even between attacks.
Martami et al. (2025) mapped the interaction between CGRP and glutamate, the brain's primary excitatory neurotransmitter, in the transition from peripheral to central sensitization.[10] CGRP enhances glutamate release from trigeminal afferents, which activates NMDA receptors on second-order neurons, lowering their firing threshold. Simultaneously, glutamate signaling increases CGRP production in a bidirectional amplification cycle. This cross-talk between a neuropeptide and a neurotransmitter system creates central sensitization that neither system could produce alone.
The clinical relevance is direct: patients with chronic migraine who respond to anti-CGRP therapy are breaking this feedback loop. When CGRP signaling is blocked, the downstream glutamate amplification decreases, central sensitization partially reverses, and attack frequency drops. Patients who do not respond may have additional neuropeptide dysregulation that CGRP blockade alone cannot address.
Endogenous Opioid Peptides: When the Brake Fails
The endorphin, enkephalin, and dynorphin system provides the body's primary endogenous pain inhibition. These peptides activate mu, delta, and kappa opioid receptors, respectively, to suppress pain transmission at the spinal cord and brainstem level. In chronic pain, this system degrades.
Gupta et al. (2021) reviewed how chronic activation of opioid receptors by endogenous peptides leads to receptor desensitization, internalization, and downregulation.[8] The three endogenous opioid peptides (beta-endorphin from pro-opiomelanocortin, enkephalins from proenkephalin, and dynorphins from prodynorphin) each show distinct patterns of dysregulation. Beta-endorphin levels in CSF decrease in chronic widespread pain conditions. Enkephalin signaling at delta receptors becomes less effective as receptor expression declines. Dynorphin presents a more complex picture: in some chronic pain states, dynorphin levels increase rather than decrease, but this paradoxically worsens pain because dynorphin acts as a pronociceptive agent at kappa receptors and at NMDA receptors.
The clinical consequence is a double deficit. Pain-promoting neuropeptides like substance P and CGRP are overexpressed. Pain-inhibiting peptides like beta-endorphin and enkephalins are reduced or their receptors are desensitized. The nervous system shifts from a balanced state (pain signals are transmitted and then dampened) to an unbalanced state (pain signals are amplified with inadequate inhibition). This imbalance helps explain why chronic pain patients often experience hyperalgesia (increased pain from painful stimuli) and allodynia (pain from normally non-painful stimuli).
Neuropeptide Y: The Lost Inhibitor
Neuropeptide Y (NPY) may be the most underappreciated player in chronic pain. Nie et al. (2025) reviewed the evidence establishing NPY as "a master regulator of pain relief" that tonically inhibits both inflammatory and neuropathic pain.[3] In the spinal cord dorsal horn, NPY-expressing interneurons release the peptide to suppress excitatory transmission. Genetic knockdown of NPY or pharmacological blockade of its receptors unmasks latent pain states, demonstrating that NPY provides a constant inhibitory tone.
After peripheral nerve injury, NPY expression patterns shift dramatically. Basu et al. (2024) detailed how Y2 receptors, normally expressed on the central terminals of primary afferents where they suppress nociceptive transmission, change their function after injury.[9] In the uninjured state, Y2 receptor activation tonically suppresses nociception. After nerve injury, Y2 signaling paradoxically facilitates ongoing hyperalgesia. This switch from inhibitory to facilitatory function means that the same neuropeptide system that was protecting against pain now contributes to its maintenance.
The therapeutic implication is that restoring NPY signaling, rather than blocking it, may be a viable pain strategy. NPY receptor agonists have shown analgesic effects in preclinical models, though no NPY-based pain drug has reached late-stage clinical trials. The challenge is receptor subtype selectivity: Y1 receptor activation is analgesic, while Y2 receptor effects are context-dependent and can be pronociceptive after nerve injury.
The Amygdala: Where Neuropeptides Create Suffering
Pain is both a sensation and an emotion. Neugebauer et al. (2020) reviewed how the amygdala, the brain's emotional processing center, uses neuropeptides to generate the affective component of chronic pain: the suffering, anxiety, and depression that accompany the sensory experience.[4]
The central nucleus of the amygdala (CeA) receives direct nociceptive input and contains high concentrations of corticotropin-releasing factor (CRF), CGRP, substance P, enkephalins, and dynorphin. In chronic pain states, CRF signaling in the CeA increases, driving anxiety-like behaviors and heightening pain sensitivity. CGRP input from the parabrachial nucleus amplifies amygdala excitability. Substance P enhances fear-related responses. The net effect is that the amygdala becomes hyperactivated, and this hyperactivation feeds back to amplify spinal cord pain processing through descending modulatory circuits.
This amygdala-mediated neuropeptide dysregulation explains several clinical observations: why chronic pain patients frequently develop comorbid anxiety and depression, why stress worsens chronic pain, and why some patients report pain relief from anxiolytic medications that have no direct analgesic properties. The emotional and sensory components of chronic pain are linked through shared neuropeptide circuits, and both must be addressed for effective treatment.
Why Single-Target Drugs Keep Failing
The neuropeptide dysregulation landscape in chronic pain is characterized by one critical feature: redundancy. MacDonald et al. (2025) showed that eliminating both substance P and CGRP-alpha, the two most studied pro-pain neuropeptides, did not prevent pain in mice.[2] This finding arrives after decades of failed clinical trials targeting individual neuropeptide systems: NK1 receptor antagonists for pain (failed), CGRP receptor antagonists for non-migraine pain (limited success), kappa opioid agonists for analgesia (intolerable side effects).
The exception is migraine, where CGRP-targeted drugs work well. The difference may be that migraine involves a relatively defined neurovascular circuit (the trigeminovascular system) where CGRP plays a dominant rather than redundant role. In broader chronic pain conditions like fibromyalgia, neuropathic pain, and chronic low back pain, multiple neuropeptide systems are simultaneously dysregulated, and blocking one does not correct the others.
This suggests that future chronic pain therapies may need to address multiple neuropeptide systems simultaneously, or target the common downstream mechanisms (like central sensitization itself) rather than individual upstream peptides. The shift toward understanding chronic pain as a disease of neuropeptide system dysregulation rather than a single-peptide problem is reshaping how peptide-based pain biomarkers and therapies are being developed.
The Bottom Line
Chronic pain involves simultaneous dysregulation of multiple neuropeptide systems. Substance P and CGRP become overexpressed and create self-amplifying feedback loops. Endogenous opioid peptides lose inhibitory capacity through receptor desensitization. NPY switches from pain-suppressive to pain-facilitative signaling after nerve injury. The amygdala integrates these changes into the emotional suffering that defines chronic pain as a disease. This multi-system dysregulation explains why single-target peptide drugs have mostly failed for chronic pain outside of migraine, and why the field is moving toward multi-target and mechanism-level approaches.